International union of pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors

Pharmacological Reviews

Volumn 51, Issue 4, 1999, Pages 745-781

  Noble, Frank ^a   Wank, Stephen A ^d   Crawley, Jacqueline N ^c   Bradwejn, Jacques ^b   Seroogy, Kim B ^e   Hamon, Michel ^f   Roques, Bernard P ^a  

^a INSERM   (France)

^b ROYAL OTTAWA HOSPITAL   (Canada)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 1 [2,3 DIHYDRO 1 (2' METHYLPHENACYL) 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL] 3 (3 METHYLPHENYL)UREA; 1 [2,3 DIHYDRO 2 OXO 1 PIVALOYLMETHYL 5 (2 PYRIDYL) 1H 1,4 BENZODIAZEPIN 3 YL] 3 [3 (METHYLAMINO)PHENYL]UREA; 1 [5 (3 AZABICYCLO[3.2.2]NON 3 YL) 2,3 DIHYDRO 1 METHYL 2 OXO 1H 1,4 BENZODIAZEPIN 3 YL] 3 (3 METHYLPHENYL)UREA; 4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ALPHA METHYL N [(TRICYCLO[3.3.1.1 3,7]DEC 2 YLOXY)CARBONYL]TRYPTOPHYL DEXTRO 3 BENZYL BETA ALANINE; AMITRIPTYLINE; ASPERLICIN; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ OCTAPEPTIDE[28,31 N METHYLNORLEUCINE]; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; DESIPRAMINE; DEVAZEPIDE; IMIPRAMINE; LINTITRIPT; LORGLUMIDE; LOXIGLUMIDE; N (4 BROMOPHENYL) 3 OXO 4,5 DIPHENYL 1 PYRAZOLIDINECARBOXAMIDE; N [1 (2 FLUOROPHENYL) 3,4,6,7 TETRAHYDRO 4 OXOPYRROLO[3,2,1 JK][1,4]BENZODIAZEPIN 3 YL] 1H INDOLE 2 CARBOXAMIDE; N [3 [(2 AMINO 4 METHYLTHIO)BUTYLDITHIO] 2 BENZYLPROPIONYL]PHENYLALANINE BENZYL ESTER; N TERT BUTYLOXYCARBONYLCHOLECYSTOKININ[27-32][28,31 NORLEUCINE] PHENETHYL ESTER;

ANTINOCICEPTION; ANXIETY NEUROSIS; BEHAVIOR; DEPRESSION; DRUG EFFECT; DRUG RECEPTOR BINDING; HUMAN; NONHUMAN; PANIC; PRIORITY JOURNAL; RECEPTOR DENSITY; REVIEW; SCHIZOPHRENIA; STRUCTURE ACTIVITY RELATION; TISSUE DISTRIBUTION;

AMINO ACID SEQUENCE; ANIMALS; HUMANS; MOLECULAR SEQUENCE DATA; RECEPTORS, CHOLECYSTOKININ; STRUCTURE-ACTIVITY RELATIONSHIP; TERMINOLOGY;

EID: 0032708056     PISSN: 00316997     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (417)

1. Abelson JL, Nesse RM and Vinik A (1991) Stimulation of corticotropin release by pentagastrin in normal subjects and patients with panic disorder. Biol Psychiatry 29:1220-1223.
2. Adams JB, Pyke RE, Costa J, Cutler NR, Schweizer E, Wilcox CS, Wisselink PG, Greiner M, Pierce MW and Pande AC (1995) A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. J Clin Psyckopharmacol 15:428-434.
3. Akiyama T and Otsuki M (1994) Characterization of a new cholecystokinin receptor antagonist FK480 in in vitro isolated rat pancreatic acini. Pancreas 9:324-331.
4. Akiyama T, Tachibana I, Hirohata Y, Shirohara H, Yamamoto M and Otsuki M (1996) Pharmacological profile of TP-680, a new cholecystokinin-A receptor antagonist. Br J Pharmacol 117:1558-1564.
5. Alho H, Costa E, Ferrero P, Fujimoto M, Cosenza-Murphy D and Guidotti A (1985) Diazepam-binding inhibitor: A neuropeptide located in selected neuronal populations of rat brain. Science (Wash DC) 229:179-182.
6. Aquino CJ, Armour DR, Berman JM, Birkemo LS, Carr RAE, Croom DK, Dezube M, Dougherty RW, Ervin GN, Grizzle MK, Head JE, Hirst GC, James MK, Johnson MF, Miller LJ, Queen JE, Rimele TJ, Smith DN and Sugg EE (1996) Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. 1. Optimization of the agonist "trigger." J Med Chem 39:562-569.
7. Augelli-Szafran CE, Horwell DC, Kneen C, Ortwine DF, Pritchard MC, Purchase TS, Roth BD, Trivedi BK, Hill D, Suman-Chauhan N and Webdale L (1996) Cholecystokinin B antagonists: Synthesis and quantitative structure-activity relationships of a series of C-terminal analogs of CI-988. Bioorg Med Chem 4:1733-1745.
8. Baber NS, Dourish CT and Hill DR (1989) The role of CCK, caerulein, and CCK antagonists in nociception. Pain 39:307-328.
9. Bachus SE, Hyde TM, Herman MM, Egan MF and Kleinman JE (1997) Abnormal cholecystokinin mRNA levels in entorhinal cortex of schizophrenics. J Psychiatr Res 31:233-256.
10. Bado A, Durieux C, Moizo L, Roques BP and Lewin MJ (1991) Cholecystokinin-A receptor mediation of food intake in cats. Am J Physiol 260:R693-R697.
11. Baldwin GS (1993) Gastrin receptor structure, in Gastrin (Walsh JH ed) pp 195-207, Raven Prees, New York.
12. Baldwin GS, Chandler R, Scanlon DB and Weinstock J (1986) Identification of a gastrin binding protein in porcine gastric mucosal membranes by covalent cross-linking with iodinated gastrin-2-17. J Biol Chem 261:12252-12257.
13. Barrett RW, Steffey ME and Wolfram CAW (1989) Type-A CCK receptors in CHP 212 neuroblastoma cells: Evidence for association with G protein and activation of phosphoinositide hydrolysis. Mol Pharmacol 35:394-400.
14. Beinborn M, Lee YM, McBride EW, Quinn SM and Kopin AS (1993) A single amino acid of the cholecystokinin-B/gastrin receptor determines specificity for non peptide antagonists. Nature (Lond) 362:348-350.
15. Bellier B, Da Nascimento S, Meudal H, Gincel E, Roques BP and Garbay C (1998) Novel constrained CCK-B dipeptoid antagonists derived from pipecolic acid. Bioorg Med Chem Lett 8:1419-1424.
16. Bellier B, McCort-Tranchepain I, Ducos B, DaNascimento S, Meudal H, Noble F, Garbay C and Roques BP (1997) Synthesis and biological properties of new constrained CCK-B antagonists: Discrimination of two affinity states of the CCK-B receptor on transfected CHO cells. J Med Chem 40:3947-3956.
17. Benkelfat C, Bradwejn J, Meyer E, Ellenbogen M, Milot S, Gjedde A and Evans A (1995) Functional neuroanatomy of CCK-4-induced anxiety in normal healthy volunteers. Am J Psychiatry 152:1180-1184.
18. Benoliel JJ, Bourgoin S, Mauborgne A, Legrand JC, Hamon M and Cesselin F (1991) Differential inhibitory/stimulatory modulation of spinal CCK release by μ and δ opioid agonists, and selective blockade of μ-dependent inhibition by κ receptor stimulation. Neurosci Lett 124:204-207.
19. Benoliel JJ, Mauborgne A, Bourgoin S, Legrand JC, Hamon M and Cesselin F (1992) Opioid control of the in vitro release of CCK-like material from the rat substantia nigra. J Neurochem 58:916-922.
20. Blandizzi C, Song I and Yamada T (1994) Molecular cloning and structural analysis of the rabbit gastrin/CCKB receptor gene. Biochem Biophys Res Commun 202: 947-953.
21. Blommaert AG, Weng JH, Dorville A, McCort I, Ducos B, Durieux C and Roques BP (1993) Cholecystokinin peptidomimetics as selective CCK-B antagonists: Design, synthesis, and in vitro and in vivo biochemical properties. J Med Chem 36:2868-2877.
22. Blommaert AGS, Dhôtel H, Ducos B, Durieux C, Goudreau N, Bado A, Garbay C and Roques BP (1997) Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor. J Med Chem 40:647-658.
23. Bock MG, DiPardo RM, Evans BE, Rittle KE, Whitter WL, Veber DF, Anderson PS and Freidinger RM (1989) Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260. J Med Chem 32:13-16.
24. Bock MG, DiPardo RM, Mellin EC, Newton RC, Veber DF, Freedman SB, Smith AJ, Patel S, Kemp JA, Marshall GR, Fletcher AE, Chapman KL, Anderson PS and Freidinger RM (1994) Second-generation benzodiazepine CCK-B antagonists. Development of sub-nanomolar analogs with selectivity and water solubility. J Med Chem 37:722-724.
25. Bock MG, DiPardo RM, Rittle KE, Evans BE, Freidinger RM, Veber DF, Chang RSL, Chen TB, Keegan ME and Lotti VJ (1986) Cholecystokinin antagonists: Synthesis of asperlicin analogs with improved potency and water solubility. J Med Chem 29:1941-1945.
26. Boden PR, Higginbottom M, Hill DR, Horwell DC, Hughes J, Rees DC, Roberts E, Singh L, Suman-Chauhan N and Woodruff GN (1993) Cholecystokinin dipeptoid antagonists: Design, synthesis, and anxiolytic profile of some novel CCK-A and CCK-B selective and "mixed" CCK-A/CCK-B antagonists. J Med Chem 36:552-565.
27. Bolton GL, Roth BD and Trivedi BK (1993) Synthesis of conformationally constrained macrocyclic analogs of the potent and selective CCK-B antagonist CI-988. Tetrahedron 49:525-536.
28. Boulenger JP, Jerabek I, Jolicoeur FB, Lavallee YJ, Leduc R and Cadieux A (1986) Elevated plasma levels of neuropeptide Y in patients with panic disorder. Am J Psychiatry 153:114-116.
29. Bradwejn J and de Montigny C (1984) Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurons. Nature (Lond) 312:363-364.
30. Bradwejn J and de Montigny C (1985a) Effects of PK 8165, a partial benzodiazepine receptor agonist, on cholecystokinin-induced activation of hippocampal pyramidal neurons: A microiontophoretic study in the rat. Eur J Pharmacol 112:415-418.
31. Bradwejn J and de Montigny C (1985b) Antagonism of cholecystokinin-induced activation of benzodiazepine receptor agonists. Ann NY Acad Sci 448:83-85.
32. Bradwejn J and Koszycki D (1991) Comparison of the panicogenic effect of cholecystokinin 30-33 and carbon dioxide in panic disorder. Prog Neuropsychopharmacol Biol Psychiatry 15:237-239.
33. Bradwejn J and Koszycki D (1994) Imipramine antagonism of the panicogenic effects of cholecystokinin-tetrapeptide in panic disorder patients. Am J Psychiatry 151: 261-263.
34. Bradwejn J, Koszycki D, Annable L, Couetoux du Tertre A, Reines S and Karkanias C (1992a) A dose-ranging study of the behavioral and cardiovascular effects of CCK-tetrapeptide in panic disorder. Biol Psychiatry 32:903-912.
35. Bradwejn J, Koszycki D and Bourin M (1991a) Dose ranging study of the effects of cholecystokinin in healthy volunteers. J Psychiatry Neurosci 16:91-95.
36. Bradwejn J, Koszycki D, Couetoux du Tertre A, van Megen H, den Boer J and Westenberg H (1994) The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry 51:486-493.
37. Bradwejn J, Koszycki D and Meterissian G (1990) Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder. Can J Psychiatry 35:83-85.
38. Bradwejn J, Koszycki D, Payeur R, Bourin M and Borthwick (1992b) Replication of action of cholecystokinin tetrapeptide in panic disorder: Clinical and behavioral findings. Am J Psychiatry 149:962-964.
39. Bradwejn J, Koszycki D and Shriqui C (1991b) Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Arch Gen Psychiatry 48:603-610.
40. Bradwejn J, LeGrand JM, Koszycki D, Bates JH and Bourin M (1998) Effects of cholecystokinin tetrapeptide on respiratory function in healthy volunteers. Am J Psychiatry 155:280-282.
41. Bradwejn J and Vasar E (1995) Cholecystokinin and panic disorder, in Cholecystokinin and Anxiety: From Neuron to Behavior (Bradwejn J and Vasar E eds) pp 73-86, RB Landes Company, Austin.
42. Brawman-Mintzer O, Lydiard RB, Bradwejn J, Villarreal G, Knapp R, Emmanuel N, Ware MR, He Q and Ballenger JC (1997) Effects of the cholecystokinin agonist pentagastrin in patients with generalized anxiety disorder. Am J Psychiatry 154:700-702.
43. Camus A, Rose C and Schwartz JC (1989) Role of a serine endopeptidase in the hydrolysis of exogenous cholecystokinin by brain slices. Neuroscience 29:595-602.
44. 28,31)-CCK 25-33S. Eur J Neurosci 4:563-573.
45. Carruthers B, Dawbarn D, De Quidt M, Emson PC, Hunter J and Reynolds GP (1984) Changes in neuropeptide content of amygdala in schizophrenia (Abstract). Br J Pharmacol 81 (Suppl):190P.
46. Chambers MS, Hobbs SC, Fletcher SR, Matassa VG, Mitchell PJ, Watt AP, Baker R, Freedman SB, Patel S and Smith AJ (1993) L-708,474: The C5-cyclohexyl analog of L-365,260, a selective, high affinity ligand for the CCK-B/gastrin receptor. BioMed Chem Lett 3:1919-1924.
47. Chambers MS, Hobbs SC, Graham MI, Watt AP, Fletcher SR, Baker R, Freedman SB, Patel S, Smith AJ and Matassa VG (1995) Potent, selective, water-soluble benzodiazepine-based CCK-B receptor antagonists that contain lipophilic carboxylate surrogates. Bioorg Med Chem Lett 5:2303-2308.
48. 3H]L-365,260: A new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand. Mol Pharmacol 35:803-808.
49. Chang RSL and Lotti VJ (1986) Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc Natl Acad Sci USA 83:4923-4926.
50. 3H]-(±)-L-364,718: A new potent, nonpeptide cholecystokinin antagonist radioligand selective for peripheral receptors. Mol Pharmacol 30:212-217.
51. Chang RSL, Lotti VJ, Monaghan RL, Birnbaum J, Stapley EO, Goetz MA, Albers-Schonberg G, Patchett AA, Liesch JM, Hensens OD and Springer JP (1985) A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus alliaceus. Science (Wash DC) 230:177-179.
52. 8 selective for central receptors. J Med Chem 31:1184-1190.
53. Charpentier B, Durieux, C, Pélaprat D, Dor A, Reibaud M, Blanchard JC and Roques BP (1988a) Enzyme-resistant CCK analogs with high affinities for central receptors. Peptides 9:835-841.
54. Charpentier B, Pélaprat D, Durieux C, Dor A, Reibaud M, Blanchard JC and Roques BP (1988b) Cyclic cholecystokinin analogs with high selectivity for central receptors. Proc Natl Acad Sci USA 85:1968-1972.
55. Chiba T, Fisher SK, Park J, Seguin EB, Agranoff BW and Yamada T (1988) Carbamylcholine and gastrin induce inositol lipid turnover in canine gastric parietal cells. Am J Physiol 255:G99-G105.
56. Choi J-K, Linehan C, Périn N. Pohl M and Wank SA (1998) Internalization is not important for desensitization or resensitization of the cholecystokinin type B receptor (CCKBR) (Abstract). Gastroenterology 114:A1136.
57. Clark CR, Daum P and Hughes J (1986) A study of the cerebral cortex cholecystokinin receptor using two radiolabelled probes: Evidence for a common CCK-8 and CCK-4 cholecystokinin receptor binding site. J Neurochem 46:1094-1101.
58. Clerc P, Dufresne M, Saillan C, Chastre E, André T, Escrieut C, Kennedy K, Vaysse N, Gespach C and Fourmy D (1997) Differential expression of the CCK-A and CCK-B/gastrin receptor genes in human cancers of the esophagus, stomach and colon, Int J Cancer 72:931-936.
59. Corp ES, McQuade J, Moran TH and Smith GP (1993) Characterization of type A and type B CCK receptor binding sites in rat vagus nerve. Brain Res 623:161-166.
60. 4 derivatives. J Med Chem 36:166-172.
61. Corsi M, Palea S, Pietra C, Oliosi B, Gaviraghi G, Sugg E, Van Amsterdam FTM and Trist DG (1994) A further analysis of the contraction induced by activation of cholecystokinin A receptors in guinea pig isolated ileum longitudinal muscle-myenteric plexus. J Pharmacol Exp Ther 270:734-740.
62. Corwin RL, Gibbs J and Smith GP (1991) Increased food intake after type A but not type B cholecystokinin receptor blockade. Physiol Behav 50:255-258.
63. Crawley JN (1984) Cholecystokinin accelerates the rate of habituation to a novel environment. Pharmacol Biochem Behav 20:23-27.
64. Crawley JN (1991) Cholecystokinin-dopamine interactions. Trends Pharmacol Sci 12:232-236.
65. Crawley JN (1995) Interactions between cholecystokinin and other neurotransmitter systems, in Cholecystokinin and Anxiety: From Neuron to Behavior (Bradwejn J and Vasar E eds) pp 35-56, RG Landes Company, Austin.
66. Crawley JN and Corwin RL (1994) Biological actions of cholecystokinin. Peptides 15:731-755.
67. Crawley JN, Hays SE and Paul SM (1981) Vagotomy abolishes the inhibitory effects of cholecystokinin on rat exploratory behaviors. Eur J Pharmacol 73:379-380.
68. Daaka Y, Luttrell LM and Lefkowitz RJ (1997) Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A. Nature (Lond) 390:88-91.
69. Dabrowski A, Grady T, Logsdon CD and Williams JA (1996a) Jun kinases are rapidly activated by cholecystokinin in rat pancreas both in vitro and in vivo. J Biol Chem 271:5686-5690.
70. Dabrowski A, VanderKuur JA, Carter-Su C and Williams JA (1996b) Cholecystokinin stimulates formation of Shc-Grb2 complex in rat pancreatic acinar cells through a protein kinase C-dependent mechanism. J Biol Chem 271:27125-27129.
71. Dal Forno G, Pietra C, Urciuoli M, Van Amsterdam FTM, Toson G, Gaviraghi G and Trist D (1992) Evidence for two cholecystokinin receptors mediating the contraction of the guinea pig isolated longitudinal muscle myenteric plexus. J Pharmacol Exp Ther 261:1056-1063.
72. Daugé V, Derrien M, Blanchard JC and Roques BP (1992) The selective CCK-B agonist, BC 264 injected in the antero-lateral part of the nucleus accumbens, reduces the spontaneous alternation behaviour of rats. Neuropharmacology 31: 67-75.
73. Daugé V, Dor A, Féger J and Roques BP (1989) The behavioral effects of CCK-8 injected into the medial nucleus accumbens are dependent on the motivational state of the rat. Eur J Pharmacol 163:25-32.
74. Daugé V and Léna I (1998) CCK in anxiety and cognitive processes. Neurosci Biobehav Rev 22:815-825.
75. Daugé V and Roques BP (1995) Opioid and CCK systems in anxiety and reward, in Cholecystokinin and Anxiety: From Neuron to Behavior (Bradwejn J and Vasar E eds) pp 151-171, RG Landes Company, Austin.
76. Day NC, Hall MD and Hughes J (1989) Modulation of hypothalamic cholecystokinin receptor density with changes in magnocellular activity: A quantitative autoradiographic study, Neuroscience 29:371-383.
77. Debas HT, Farooq O and Grossman MI (1975) Inhibition of gastric emptying is a physiological action of cholecystokinin. Gastroenterology 68:1211-1217.
78. De Leeuw AS, den Boer JA, Slaap BR and Westenberg HG (1996) Pentagastrin has panic-inducing properties in obsessive compulsive disorder. Psychopharmacology 126:339-344.
79. 2+]i by secretagogue stimulation of canine gastric parietal cells. Am J Physiol 262:G420-G426.
80. de Montigny C (1989) Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Arch Gen Psychiatry 46:511-517.
81. Denavit-Saubié M, Hurlé MA, Morin-Surun MP, Foutz AS and Champagnat J (1985) The effects of cholecystokinin-8 in the nucleus tractus solitarius. Ann NYAcad Sci 448:375-384.
82. Denyer J, Gray J, Wong M, Stolz M and Tate S (1994) Molecular and pharmacological characterization of the human CCKB receptor. Eur J Pharmacol 268:29-41.
83. Derrien M, Daugé V, Blommaert A and Roques BP (1994a) The selective CCK-B agonist, BC 264, impairs socially reinforced memory in the three-panel runway test in rats. Behav Brain Res 65:139-146.
84. 8 in the posterior part of the nucleus accumbens. Brain Res 617:181-188.
85. Derrien M, McCort-Tranchepain I, Ducos B, Roques BP and Durieux C (1994b) Heterogeneity of CCK-B receptors involved in animal models of anxiety. Pharmacol Biochem Behav 49:133-141.
86. Derrien M, Noble F, Maldonado R and Roques BP (1993b) Cholecystokinin-A but not cholecystokinin-B receptor stimulation induces endogenous opioid-dependent antinociceptive effects in the hot plate test in mice. Neurosci Lett 160:193-196.
87. Deschenes RJ, Lorenz LJ, Haun RS, Roos BA, Collier KJ and Dixon JE (1984) Cloning and sequence analysis of cDNA encoding rat preprocholecystokinin. Proc Natl Acad Sci USA 81:726-730.
88. de Weerth A, Pisegna JR, Huppil K and Wank SA (1993a) Molecular cloning, functional expression and chromosomal localization of the human cholecystokinin type A receptor. Biochem Biophys Res Commun 194:811-818.
89. de Weerth A, Pisegna JR and Wank S (1993b) Guinea pig gallbladder and pancreas possess identical CCK-A receptor subtypes: Receptor cloning and expression. Am J Physiol 265:G1116-G1121.
90. Didier E, Horwell DC and Pritchard MC (1992) Synthesis and CCK-B binding affinities of cyclic analogs of the potent and selective CCK-B antagonist CI-988. Tetrahedron 48:8471-8490.
91. Dietl MM and Palacios JM (1989) The distribution of cholecystokinin receptors in the vertebrate brain: Species differences studied by receptor autoradiography. J Chem Neuroanat 2:149-161.
92. Dietl MM, Probst A and Palacios JM (1987) On the distribution of cholecystokinin receptor binding sites in the human brain: An autoradiographic study. Synapse 1:169-183.
93. Ding XQ, Chen D and Hakanson R (1995) Cholecystokinin-B/gastrin receptor ligands of the dipeptoid series act as agonists on histidine decarboxylase in rat stomach anterochromaffin-like cells. Pharmacol Toxicol 76 (Suppl IV):81.
94. Dockray GJ (1988) Regulatory peptides and the neuroendocrinology of brain-gut relations. Q J Exp Physiol 73:703-727.
95. Dodt C, Sarnighausen HE, Pietrowsky R, Fehm HL and Born J (1996) Ceruletide improves event-related potential indicators of cognitive processing in young but not in elderly humans. J Clin Psychopharmacol 16:440-445.
96. Dohlman HG, Thorner J, Caron MG and Lefkowitz RJ (1991) Model systems for the study of seven-transmembrane-segment receptors. Annu Rev Biochem 60:653-680.
97. Dourish CT, Ruckert AC, Tattersall FD and Iversen SD (1989) Evidence that decreased feeding induced by systemic injection of cholecystokinin is mediated by CCK-A receptors. Eur J Pharmacol 173:233-234.
98. Dufresne M, Escrieut C, Clerc P, Le Huerou-Luron I, Prats H, Bertrand V, Le Meuth V, Guilloteau P, Vaysse N and Fourmy D (1996) Molecular cloning, ontogeny and characterization of a predominant pancreatic CCKB/gastrin receptor in the calf pancreas. Eur J Pharmacol 297:165-179.
99. 8 analogs by rat brain slices. Neuropeptides 7:1-9.
100. Durieux C, Coppey M, Zajac JM and Roques BP (1986b) Occurrence of two cholecystokinin binding sites in guinea pig brain cortex. Biochem Biophys Res Commun 137:1167-1173.
101. 3H]pBC 264, first highly potent and very selective radioligand for CCK-B receptors. Eur J Pharmacol 168:269-270.
102. 3H]CCK-4 binding sites in mouse and rat brain. Neuropeptides 12:141-148.
103. 3H]SNF 8702. Mol Pharmacol 41:1089-1095.
104. 3H]pBC 264. Eur J Pharmacol 209:185-193.
105. Evans BE, Bock MG, Rittle KE, DiPardo RM, Whitter WL, Veber DF, Anderson PS and Freidinger RM (1986) Design of potent, orally effective, nonpeptidal antagonists of the peptide hormone cholecystokinin. Proc Natl Acad Sci USA 83:4918-4922.
106. Faris PL, Komisaruk BR, Watkins LR and Mayer DJ (1983) Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science (Wash DC) 219:310-312.
107. Farmery SM, Owen F, Poulter M and Crow TJ (1985) Reduced high affinity cholecystokinin binding in hippocampus and frontal cortex of schizophrenic patients. Life Sci 36:473-477.
108. Ferrier IN, Crow TJ, Farmery SM, Roberts GW, Owen F, Adrian TE and Bloom SR (1985) Reduced cholecystokinin levels in the limbic lobe in schizophrenia: A marker for pathology underlying the defect state? Ann NY Acad Sci 448:495-506.
109. Ferrier IN, Roberts GW, Crow TJ, Johnstone EC, Owens DG, Lee YC, O'Shaughnessy D, Adrian TE, Polak JM and Bloom SR (1983) Reduced cholecystokinin-like and somatostatin-like immunoreactivity in limbic lobe is associated with negative symptoms in schizophrenia. Life Sci 33:475-482.
110. Fincham CI, Higginbottom M, Hill DR, Horwell DC, O'Toole JC, Ratcliffe GS, Rees DC and Roberts E (1992a) Amide bond replacements incorporated into CCK-B selective "dipeptoids." J Med Chem 35:1472-1484.
111. Fincham CI, Horwell DC, Ratcliffe GS and Rees DC (1992b) The use of a proline ring as a conformational restraint in CCK-B receptor "dipeptoids." Biomed Chem Lett 2:403-406.
112. Floresco SB, Seamans JK and Philipps AG (1996) A selective role for dopamine in the nucleus accumbens of the rat in random foraging but not delayed spatial win-shift-based foraging. Behav Brain Res 80:161-168.
113. Fourmy D, Zahidi A, Gabre R, Guidet M, Praydayrol L and Ribet A (1987) Receptors for cholecystokinin and gastrin peptides display specific binding properties and are structurally different in guinea pig and dog pancreas. Eur J Biochem 165:683-692.
114. 1H NMR spectroscopy, fluorescence transfer measurements and calculations. Biochemistry 25:3778-3787.
115. Fournié-Zaluski MC, Coric P, Turcaud S, Lucas E, Noble F, Maldonado R and Roques BP (1992) Mixed-inhibitor-prodrug as a new approach towards systemically active inhibitors of enkephalin degrading enzymes. J Med Chem 35:2474-2481.
116. Freidinger RM (1989) Non-peptide ligands for peptide receptors. Trends Pharmacol Sci 10:270-275.
117. Galas MC, Bernard N and Martinez J (1992) Pharmacological studies on CCK-B receptors in guinea pig synaptoneurosomes. Eur J Pharmacol 226:35-41.
118. Galas MC, Lignon MF, Rodriguez M, Mendre C, Fulcrand P, Laur J and Martinez J (1988) Structure-activity relationship studies on cholecystokinin: Analogues with partial agonist activity. Am J Physiol 254:G176-G182.
119. Gall C, Lauterborn J, Burks D and Seroogy K (1987) Co-localization of enkephalins and cholecystokinin in discrete areas of rat brain. Brain Res 403:403-408.
120. 3H]pentagastrin. Peptides 4:755-762.
121. Gaudreau P, St. Pierre S, Pert CB and Quirion R (1985) Cholecystokinin receptors in mammalian brain: A comparative characterization and visualization. Ann NY Acad Sci 448:198-219.
122. Gelernter J, Kennedy JL, Van Tol HHM, Civelli O and Kidd KK (1992) The D4 dopamine receptor (DRD4) maps to distal 11p close to HRAS. Genomics 13:208-210.
123. Geracioti TD, Nicholson WE, Orth DN, Ekhator NN and Loosen PT (1993) Cholecystokinin in human cerebrospinal fluid: Concentrations, dynamics, molecular forms and relationship to fasting and feeding in health, depression and alcoholism. Brain Res 629:260-268.
124. Gerhardt P, Voits M, Fink H and Huston JP (1994) Evidence for mnemotropic action of cholecystokinin fragments Boc-CCK-4 and CCK-8S. Peptides 16:689-697.
125. Gerner RH and Yamada T (1982) Altered neuropeptide concentrations in cerebrospinal fluid of psychiatric patients. Brain Res 238:298-302.
126. Ghilardi JR, Allen CJ, Vigna SR, McVey DC and Mantyh PW (1992) Trigeminal and dorsal root ganglion neurons express CCK receptor binding sites in the rat, rabbit and monkey: Possible site of opiate-CCK analgesic interactions. J Neurosci 12: 4854-4866.
127. Gibbs J, Young RC and Smith GP (1973) Cholecystokinin decreases food intake in rats. J Comp Physiol Psychol 84:488-495.
128. Go WY, Holicky EL, Hadac EM, Rao RV and Miller LJ (1998) Identification of a domain in the carboxy terminus of CCK receptor that affects its intracellular trafficking. Am J Physiol 275:G56-G62.
129. 2. Biopolymers 34:155-159.
130. Graff JM, Stumpo DJ and Blackshear PJ (1989) Characterization of the phosphorylation sites in the chicken and bovine myristoylated alanine-rich C kinase substrate protein, a prominent cellular substrate for protein kinase C. J Biol Chem 264:11912-11919.
131. 3H]MK-329 (devazepide) binding to CCK receptors in the substantia nigra/VTA complex and its forebrain projection areas following MPTP-induced hemi-parkinsonism in the monkey. Neurosci Lett 131:129-134.
132. Guidotti A, Forchetti CM, Corda MG, Konkel D, Bennett CD and Costa E (1983) Isolation, characterization, and purification to homogeneity of an endogenous polypeptide with agonistic action on benzodiazepine receptors. Proc Natl Acad Sci USA 80:3531-3535.
133. Gully D, Fréhel D, Marcy C, Spinazze A, Lespy L, Neliat G, Maffrand JP and Le Fur G (1993) Peripheral biological activity of SR 27897: A new potent non-peptide antagonist of CCK-A receptors. Eur J Pharmacol 232:13-19.
134. 2 receptor mRNAs. Neuroreport 9:2035-2038.
135. Harhammer R, Schafer U, Henklein P, Ott T and Repke H (1991) CCK-8-related C-terminal tetrapeptides: Affinities for central CCKB and peripheral CCKA receptors. Eur J Pharmacol 209:263-266.
136. Harper EA, Roberts SP, Shankley NP and Black JW (1996) Analysis of variation in L-365,260 competition curves in radioligand binding assays. Br J Pharmacol 118:1717-1726.
137. Harro J, Kiivet RA, Lang A and Vasar E (1990) Rats with anxious or non-anxious type of exploratory behaviour differ in their brain CCK-8 and benzodiazepine receptor characteristics. Behav Brain Res 39:63-71.
138. Harro J and Oreland L (1993) Cholecystokinin receptors and memory: A radial maze study. Pharmacol Biochem Behav 44:509-517.
139. Harro J, Vasar E and Bradwejn J (1993) Cholecystokinin in animal and human research on anxiety. Trends Pharmacol Sci 14:244-249.
140. Hays SE, Beinfeld MC, Jensen RT, Goodwin FK and Paul SM (1980) Demonstration of a putative receptor site for cholecystokinin in the rat brain. Neuropeptides 1:53-62.
141. Helander HF, Wong H, Poorkhalkali N and Walsh JH (1997) Immunohistochemical localization of gastrin/CCK-B receptors in the dog and guinea pig stomach. Acta Physiol Scand 159:313-320.
142. Hendrie CA, Shepherd JK and Rodgers RJ (1989) Differential effects of the CCK antagonist, MK-329, on analgesia induced by morphine, social conflict (opioid) and defeat experience (non-opioid) in male mice. Neuropharmacology 28:1025-1032.
143. Henke BR, Aquino CJ, Birkemo LS, Croom DK, Dougherty RW, Ervin GN, Grizzle MK, Hirst GC, James MK, Johnson MF, Queen KL, Sherrill RG, Sugg EE, Suh EM, Szewczyk JW, Unwalla RJ, Yingling J and Willson TM (1997) Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists. J Med Chem 40:2706-2725.
144. Hernando F, Fuentes JA, Roques BP and Ruiz-Gayo M (1994) The CCK-B receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swim test in mice. Eur J Pharmacol 261:257-263.
145. Higginbottom M, Hill DR, Horwell DC, Mostafai E, Suman-Chauhan N and Roberts E (1993) Conformationally restricted analogs of the potent CCK-B antagonist CI-988. Bioorg Med Chem 1:209-217.
146. Hill DR, Campbell NJ, Shaw TM and Woodruff GN (1987) Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective nonpeptide antagonists. J Neurosci 7:2967-2976.
147. Hill DR, Horwell DC, Hunter JC, Kneen CO, Pritchard MC and Suman-Chauhan N (1993) Synthesis of a potent and selective non-peptide CCK-B/gastrin receptor antagonist tritiated ligand. Biomed Chem Lett 3:885-888.
148. Hill DR, Shaw TM, Dourish CT and Woodruff GN (1988a) CCK-A receptors in the rat interpeduncular nucleus: Evidence for a presynaptic location. Brain Res 454:101-105.
149. 3H-MK-329. J Neurosci 10:1070-1081.
150. 125I-cholecystokinin in primate spinal cord are of the CCK-A subclass. Neurosci Lett 89:133-139.
151. Hill DR and Woodruff GN (1990) Differentiation of central cholecystokinin receptor binding sites using the non-peptide antagonists MK-329 and L-365,260. Brain Res 526:276-283.
152. Himick BA, Vigna SR and Peter RE (1996) Characterization of cholecystokinin binding sites in goldfish brain and pituitary. Am J Physiol 271-.R137-R143.
153. Hinks GL, Poat JA and Hughes J (1995) Changes in hypothalamic cholecystokininA and cholecystokininB receptor subtypes and associated neuropeptide expression in response to salt-stress in the rat and mouse. Neuroscience 68:766-781.
154. Hirst GC, Aquino C, Birkemo L, Croom DK, Dezube M, Dougherty RW, Ervin GN, Grizzle MK, Henke B, James MK, Johnson MF, Momtahen T, Queen KL, Sherrill RG, Szewczyk J, Willson TM and Sugg EE (1996) Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity. II: Optimization of the C3 amino substituent. J Med Chem 39:5236-5245.
155. Holladay MW, Bennett MJ, Tufano MD, Lin CW, Asin KE, Witte DG, Miller TR, Bianchi BR, Nikkel AL, Bednarz L and Nadzan AM (1992) Synthesis and biological activity of CCK heptapeptide analogs: Effects of conformational constraints and standard modifications on receptor subtype selectivity, functional activity in vitro, and appetite suppression in vivo. J Med Chem 35:2919-2928.
156. B receptors in the rat brain. Mol Cell Neurosci 4:143-154.
157. Horwell DC (1991) Development of CCK-B antagonists. Neuropeptides 19 (Suppl): 57-64.
158. Horwell DC, Hughes J, Hunter JC, Pritchard MC, Richardson RS, Roberts E and Woodruff GN (1991) Rationally designed "dipeptoid" analogs of CCK: α-Methyl-tryptophan derivatives as highly selective and orally active gastrin and CCK-B antagonists with potent anxiolytic properties. J Med Chem 34:404-414.
159. Horwell DC, Hunter JC, Kneen CO and Pritchard MC (1995) Synthesis of novel iodinated radioligands with high affinity and selectivity for CCK-B/gastrin receptors. Bioorg Med Chem Lett 5:2501-2506.
160. Howbert JJ, Lobb KL, Brown RF, Reel JK, Neel DA, Mason NR, Mendelsohn LG, Hodgkiss JP and Kelly JS (1992) A novel series of non-peptide CCK and gastrin antagonists: Medicinal chemistry and electrophysiological demonstration of antagonism, in Multiple Cholecystokinin Receptors: Progress Toward CNS Therapeutic Targets (Dourish CT and Cooper SJ eds) pp 28-37, Oxford University Press, London.
161. Höcker M, Hughes JJ, Fölsch UR and Schmidt WE (1993) PD-135,158, a CCK-B/ gastrin receptor antagonist stimulates rat pancreatic enzyme secretion as CCK-A receptor agonist. Eur J Pharmacol 242:105-108.
162. Hökfelt T, Skirboll LR, Rehfeld JH, Goldstein M, Markey K and Dann O (1980) A subpopulation of mesencephalic dopamine neurons projecting to limbic areas contains a cholecystokinin-like peptide: Evidence from immunohistochemistry combined with retrograde tracing. Neuroscience 5:2093-2142.
163. Huang SC, Fortune KP, Wank SA, Kopin AS and Gardner JD (1994) Multiple affinity states of different cholecystokinin receptors. J Biol Chem 269:26121-26126.
164. Hughes J, Boden P, Costall B, Domeney A, Kelly E, Horwell DC, Hunter JC, Pinnock RD and Woodruff GN (1990) Development of a class of selective cholecystokinin type B receptor antagoniste having potent anxiolytic activity. Proc Natl Acad Sci USA 87:6728-6732.
165. Hull RAD, Shankley NP, Harper EA, Gerskowitch VP and Black JW (1993) 2-Naphthalenesulphonyl L-aspartyl-(2-phenethyl)amide (2-NAP): A selective cholecystokinin CCK-A receptor antagonist. Br J Pharmacol 108:734-740.
166. B/gastrin receptor in guinea pig cerebral cortex and gastric mucosa. Mol Pharmacol 43:595-602.
167. Huppi K, Siwarski D, Pisegna JR and Wank S (1995) Chromosomal localization of the gastric and brain receptors for cholecystokinin (CCK-AR and CCK-BR) in human and mouse. Genomics 25:727-729.
168. Hyde TM and Peroutka SJ (1989) Distribution of cholecystokinin receptors in the dorsal vagal complex and other selected nuclei in the human medulla. Brain Res 495:198-202.
169. Innis RB, Bunney BS, Charney DS, Price LH, Glazer WM, Sternberg DE, Rubin AL and Heninger GR (1986) Does the cholecystokinin antagonist proglumide possess antipsychotic activity? Psychiatry Res 18:1-7.
170. Innis RB and Snyder SH (1980a) Cholecystokinin receptor binding in brain and pancreas: Regulation of pancreatic binding by cyclic and acyclic guanine nucleotides. Eur J Pharmacol 65:123-124.
171. Innis RB and Snyder SH (1980b) Distinct cholecystokinin receptors in brain and pancreas. Proc Natl Acad Sci USA 77:6917-6921.
172. Inoue H, Iannotti CA, Welling CM, Veile R, Donis-Keller H and Permutt MA (1997) Human cholecystokinin type A receptor gene: Cytogenetic localization, physical mapping, and identification of two missense variants in patients with obesity and non-insulin-dependent diabetes mellitus (NIDDM). Genomics 42:331-335.
173. Ito H, Sogabe H, Nakarai T, Sato Y, Tomoi M, Kadowaki M, Matsuo M, Tokoro K and Yoshida K (1994a) Pharmacological profile of FK-480, a novel cholecystokinin type-A receptor antagonist: Comparison to loxiglumide. J Pharmacol Exp Ther 268:571-575.
174. Ito M, Iwata N, Taniguchi T, Murayama T, Chihara K and Matsui T (1994b) Functional characterization of two cholecystokinin-B/gastrin receptor isoforms: A preferential splice donor site in the human receptor gene. Cell Growth Differ 5:1127-1135.
175. Ito M, Matsui T, Taniguchi T, Tsukamoto T, Murayama T, Arima N, Nakata H, Chiba T and Chihara K (1993) Functional characterization of human brain cholecystokinin-B receptor: A trophic effect of cholecystokinin and gastrin. J Biol Chem 268:18300-18305.
176. Ivy AC and Oldberg E (1928) A hormone mechanism for gallbladder contraction and evacuation. Am J Physiol 86:599-613.
177. 100 in the second transmembrane domain of the cholecystokinin B receptor increases antagonist binding and reduces signal transduction. Mol Pharmacol 48:783-789.
178. Jagerschmidt A, Guillaume N, Roques BP and Noble F (1998) Binding sites and transduction process of the cholecystokinin B receptor: involvement of highly conserved aromatic residues of the transmembrane domains evidenced by site-directed mutagenesis. Mol Pharmacol 53:878-885.
179. B versus CCKA receptor antagonist selectivity. Eur J Pharmacol 296:97-106.
180. Jagerschmidt A, Popovici T, O'Donohue M and Roques BP (1994) Identification and characterization of various cholecystokinin B receptor mRNA forms in rat brain tissue and partial determination of the cholecystokinin B receptor gene structure. J Neurochem 63:1199-1206.
181. Jensen RT, Qian JM, Lin JT, Mantey SA, Pisegna JR and Wank SA (1994) Distinguishing multiple CCK receptor subtypes: Studies with guinea pig chief cells and transfected human CCK receptors. Ann NY Acad Sci 713:88-106.
182. Jensen RT, Wank SA, Rowley WH, Sato S and Gardner JD (1989) Interaction of CCK with pancreatic acinar cells. Trends Pharmacol Sci 10:418-423.
183. Ji Z, Hadac EM, Henne RM, Patel SA, Lybrand TP and Miller LJ (1997) Direct identification between the carboxyl-terminal residue of cholecystokinin and the type A cholecystokinin receptor using photoaffinity labeling. J Biol Chem 272: 24393-24401.
184. Jorpes JE and Mutt V (1966) Cholecystokinin and pancreozymin: One single hormone? Acta Physiol Scand 66:196.
185. Katsuura G and Itoh S (1986) Passive avoidance deficit following intracerebroventricular administration of cholecystokinin tetrapeptide amide in rats. Peptides 7:809-814.
186. Katzman M, Bradwejn J, Koszycki D, Vaccarino F and Richter M (1997) The effect of CCK-4 in social phobia and OCD. American Psychiatry Association's 150th Annual Meeting, May 17-22, 1997, San Diego. Washington, DC: American Psychiatry Association;105 p.
187. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M and Natori T (1992) Spontaneous long-term hyperglycemic rat with diabetic complications: Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 41:1422-1428.
188. Kellner M, Yassouridis A, Jahn H and Wiedemann K (1997) Influence of clonidine on psychopathological, endocrine and respiratory effects of cholecystokinin tetrapeptide in patients with panic disorder. Psychopharmacology 133:55-61.
189. Kenakin T (1995) Agonist-receptor efficacy. II: Agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232-238.
190. Kennedy JL, Bradwejn J, Koszycki D, King N, Crowe R, Vincent J and Fourie O (1999) Investigation of cholecystokinin system genes in panic disorder. Mol Psychiatry 4:284-285.
191. Kennedy K, Gigoux G, Escrieut C, Maigret B, Martinez J, Moroder L, Frehel D, Gully D, Vaysse N and Fourmy D (1997) Identification of two amino acids of the human cholecystokinin-A receptor that interact with the N-terminal moiety of cholecystokinin. J Biol Chem 272:2920-2926.
192. Kiraly I and Van Ree JM (1987) Behavioral evidence for the involvement of endogenous opioids in the interaction between cholecystokinin and brain dopamine systems. Neurosci Lett 74:343-347.
193. Klueppelberg UG, Molero X, Barrett RW and Miller LJ (1990) Biochemical characterization of the cholecystokinin receptor on CHP212 human neuroblastoma cells. Mol Pharmacol 38:159-163.
194. 26-33): Evidence for CCK-B receptor heterogeneity. J Pharmacol Exp Ther 255:1278-1286.
195. Kobayashi S, Ohta M, Miyasaka K and Funakoshi A (1996) Decrease in exploratory behavior in naturally occurring cholecystokinin (CCK)-A receptor gene knockout rats. Neurosci Lett 214:61-64.
196. Koks S, Vasar E, Soosaar A, Lang A, Volke V, Voikar V, Bourin M and Mannisto PT (1997) Relation of exploratory behavior of rats in elevated plus-maze to brain receptor binding properties and serum growth hormone levels. Eur Neuropsychopharmacol 7:289-294.
197. 4 analogs: Synthesis, and implication for the CCK-B receptor-bound conformation. J Med Chem 38:137-149.
198. Kopin AS, Lee YM, McBride EW, Miller LJ, Lu M, Lin HY, Kolakowski LF and Beinborn M (1992) Expression, cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci USA 89:3605-3609.
199. Kopin AS, McBride EW, Quinn SM, Kolakowski LF and Beinborn M (1995) The role of the cholecystokinin-B/gastrin receptor transmembrane domains in determining affinity for subtype-selective ligands. J Biol Chem 270:5019-5023.
200. Kramer MS, Cutler NR, Ballenger JC, Patterson WM, Mendels J, Chenault A, Shrivastava R, Matzura-Wolfe D, Lines C and Reines S (1995) A placebo-controlled trial of L-365,260, a CCK-B antagonist, in panic disorder. Biol Psychiatry 37:462-466.
201. Kritzer MF, Innis RB and Goldman-Rakic PS (1988) Regional distribution of cholecystokinin receptors in primate cerebral cortex determined by in vitro receptor autoradiography. J Comp Neurol 263:418-435.
202. Kritzer MF, Innis RB and Goldman-Rakic PS (1990) Regional distribution of cholecystokinin binding sites in macaque basal ganglia determined by in vitro receptor autoradiography. Neuroscience 38:81-92.
203. Kuehl-Kovarik MC, Ross LR, Elmquist JK and Jacobson CD (1993) Localization of cholecystokinin binding sites in the adult and developing Brazilian opossum brain. J Comp Neurol 336:40-52.
204. Lacourse KA, Lay JM, Swanberg LJ, Jenkins C and Samuelson LC (1997) Molecular structure of the mouse CCK-A receptor gene. Biochem Biophys Res Commun 236:630-635.
205. Ladurelle N, Keller G, Blommaert A, Roques BP and Daugé V (1997) The CCK-B agonist, BC 264, increases dopamine in the nucleus accumbens and facilitates motivation and attention after peripheral intraperitoneal injection in rats. Eur J Neurosci 9:1804-1814.
206. 8 and of the CCK-B selective agonist BC 264 on extracellular dopamine content in the anterior and posterior nucleus accumbens: A microdialysis study in freely moving rats. Brain Res 628:254-262.
207. Lallement JC, Oiry C, Lima-Leite AC, Lignon MF, Fulcrand P, Galleyrand JC and Martinez J (1995) Cholecystokinin and gastrin are not equally sensitive to GTPγS at CCK-B receptors: Importance of the sulphated tyrosine. Eur J Pharmacol 290:61-67.
208. Langhans N, Rindi G, Chiu M, Rehfeld JF, Ardman B, Beinborn M and Kopin AS (1997) Abnormal gastric histology and decreased acid production in cholecystokinin-B/gastrin receptor-deficient mice. Gastroenterology 112:280-286.
209. Lavigne GJ, Millington WR and Mueller GP (1992) The CCK-A and CCK-B receptors antagonists devazepide and L-365,260 enhance morphine antinociception only in non-acclimated rats exposed to novel environment. Neuropeptides 21:119-129.
210. Le Melledo JM, Bradwejn J, Koszycki D and Bichet D (1995) Premenstrual dysphoric disorder and response to cholecystokinin-tetrapeptide. Arch Gen Psychiatry 52: 605-606.
211. Le Melledo JM, Bradwejn J, Koszycki D, Bichet F and Bellavance F (1998) The role of beta adrenergic system in CCK-4 induced panic symptoms. Biol Psychiatry 23:298-304.
212. Lee YM, Beinborn M, McBride EW, Lu M, Kolakowski LF and Kopin AS (1993) The human brain cholecystokinin-B/gastrin receptor: Cloning and characterization. J Boil Chem 268:8164-8169.
213. Lemaire M, Barnéoud P, Böhme GA, Piot O, Haun F, Roques BP and Blanchard JC (1994) CCK-A and CCK-B receptor agonists and antagonists modulate olfactory recognition in male rats. Psychopharmacology 115:435-440.
214. Lemaire M, Piot O, Roques BP, Böhme AG and Blanchard JC (1992) Evidence for an endogenous cholecystokininergic balance in social memory. Neuroreport 3:925-932.
215. Liddle RA, Goldfine ID and Williams JA (1984) Bioassay of plasma cholecystokinin in rats: Effects of food, trypsin inhibitor, and alcohol. Gastroenterology 87:542-549.
216. Lignon MF, Galas MC, Rodriguez M, Laur J, Aumelas A and Martinez J (1987) A synthetic peptide derivative that is a cholecystokinin receptor antagonist. J Biol Chem 262:7226-7231.
217. 125I]Bolton Hunter-cholecystokinin octapeptide. J Pharmacol Exp Ther 232:775-780.
218. Lin CW, Shiosaki K, Miller TR, Witte DG, Bianchi BR, Wolfram CA, Kopecka H, Craig R, Wagenaar F and Nadzan AM (1991) Characterization of two novel cholecystokinin tetrapeptide (30-33) analogs, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors. Mol Pharmacol 39: 346-351.
219. Lines C, Challenor J and Traub M (1995) Cholecystokinin and anxiety in normal volunteers: An investigation of the anxiogenic properties of pentagastrin and reversal by the cholecystokinin receptor subtype CCK-B antagonist, L-365,260. Br J Pharmacol 39:235-242.
220. Lo WWY and Hughes J (1988) Differential regulation of cholecystokinin-and muscarinic-receptor-mediated phosphoinositide turnover in flow 900 cells. Biochem J 251:625-630.
221. Löfberg C, Agren H, Harro J and Oreland L (1998) Cholecystokinin in CSF from depressed patients: Possible relations to severity of depression and suicidal behaviour. Eur Neuropsychopharmacol 8:153-157.
222. Logsdon CD (1986) Glucocorticoids increase cholecystokinin receptors and amylase secretion in pancreatic acinar AR42J cells. J Biol Chem 261:2096-2101.
223. Lopez Y, Fioramonti J and Bueno L (1991) Central and peripheral control of postprandial pyloric motility by endogenous opiates and CCK in dogs. Gastroenterology 101:1249-1255.
224. Lotti VJ and Chang RSL (1989) A new potent and selective non peptide gastrin antagonist and brain CCK-B ligand: L-365,260. Eur J Pharmacol 162:273-280.
225. Lowe JA, Drozda SE, McLean S, Bryce DK, Crawford RT, Zorn S, Morrone J, Appleton TA and Lombardo A (1995) Water soluble benzodiazepine cholecystokinin-B receptor antagonist Bioorg Med Chem Lett 5:1933-1936.
226. Madtes PCJ and King JS (1994) Distribution of cholecystokinin binding sites in the North American opossum cerebellum. J Chem Neuroanat 7:105-112.
227. 2 with μ and δ opioid antinociception in the rat spinal cord. Neuropeptides 16:213-218.
228. Makovec F, Chiste R, Bani M, Pacini MA, Setnikar I and Rovati LA (1985) New glutaramic acid derivatives with potent competitive and specific cholecystokinin-antagonistic activity. Arzneimittelforschung 35:1048-1051.
229. Makovec F and D'Amato M (1997) CCK-B/gastrin receptor antagonists as potential drugs for peptic ulcer therapy. Drug Discov Today 2:283-293.
230. Maldonado R, Valverde O, Ducos B, Blommaert AG, Fournié-Zaluski MC and Roques BP (1995) Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCK-B antagonist PD-134,308. Br J Pharmacol 114:1031-1039.
231. Mantamadiotis T and Baldwin GS (1994) The seventh trans-membrane domain of gastrin/CCK receptors contributes to non-peptide antagonist binding. Biochem Biophys Res Commun 201:1382-1389.
232. Mantyh CR and Mantyh PW (1985) Differential localization of cholecystokinin-8 binding sites in the rat vs. the guinea pig brain. Eur J Pharmacol 113:137-139.
233. Mantyh CR, Pappas TN and Vigna SR (1994) Localization of cholecystokinin A and cholecystokinin B/gastrin receptors in the canine upper gastrointestinal tract. Gastroenterology 107:1019-1030.
234. Marino CR, Leach SD, Schaefer JF, Miller LJ and Gorelick FS (1993) Characterization of cAMP-dependent protein kinase activation by CCK in rat pancreas. FEBS Lett 316:48-52.
235. 26-33-related analogs modified in position 31. J Med Chem 31:966-970.
236. Marseigne I, Roy P, Dor A, Durieux C, Pélaprat D, Reibaud M, Blanchard JC and Roques BP (1989) Full agonists of CCK-8 containing a nonhydrolyzable sulfated tyrosine residue. J Med Chem 32:445-449.
237. Martin-Martinez M, Bartolomé-Nebreda JM, Gomez-Monterrey I, Gonzalez-Muniz R, Garcia-Lopez MT, Ballaz S, Barber A, Fortune A, Del Rio J and Herranz R (1997) Synthesis and stereochemical structure-activity relationships of 1,3-dioxopernydropyrido[1,2-c]pyrimidine derivatives: Potent and selective cholecystokinin-A receptor antagonists. J Med Chem 40:3402-3407.
238. McCann UD, Slate SO, Geraci M and Uhde TW (1994) Peptides and anxiety: A dose-response evaluation of pentagastrin in healthy volunteers. Anxiety 1:258-267.
239. Meister B, Broberger C, Villar MJ and Hökfelt T (1994) Cholecystokinin B receptor gene expression in hypothalamic neurosecretory neurons after experimental manipulations. Neuroendocrinology 60:458-469.
240. Menozzi D, Gardner JD and Maton PN (1989) Properties of receptors for gastrin and CCK on gastric smooth muscle cells. Am J Physiol 257:G73-G79.
241. Mercer JG and Lawrence CB (1992) Selectivity of cholecystokinin (CCK) receptor antagonists, MK-329 and L-365,260, for axonally-transported CCK binding sites on the rat vagus nerve. Neurosci Lett 137:229-231.
242. A receptor. Neurosci Lett 225:97-100.
243. Mercer LD, Beart PM, Horne MK, Finkelstein DI, Carrive P and Paxinos G (1996) On the distribution of cholecystokinin B receptors in monkey brain. Brain Res 738:313-318.
244. Miceli MO and Steiner M (1989) Novel localizations of central-and peripheral-type cholecystokinin binding sites in Syrian hamster brain as determined by autoradiography. Eur J Pharmacol 169:215-224.
245. Migaud M, Durieux C, Viereck J, Soroca-Lucas E, Fournié-Zaluski MC and Roques BP (1996) The in vivo metabolism of cholecystokinin (CCK-8) is essentially ensured by aminopeptidase A. Peptides 17:601-607.
246. Migaud M, Roques BP and Durieux C (1995) Evidence for a high affinity uptake system for cholecystokinin octapeptide (CCK8) in rat cortical synaptosomes. Eur J Neurosci 7:1074-1079.
247. Miller LJ (1984) Characterization of cholecystokinin receptors on human gastric smooth muscle tumors. Am J Physiol 247:G402-G410.
248. Miller LJ, Holicky E, Ulrich CD and Wieben ED (1995) Abnormal processing of the human cholecystokinin receptor gene in association with gallstones and obesity. Gastroenterology 109:1375-1380.
249. Million ME, Léna I, Da Nascimento S, Noble F, Daugé V, Garbay C and Roques BP (1997) Development of new potent agonists able to interact with two postulated subsites of the cholecystokinin CCK-B receptor. Lett Peptide Sci 4:407-410.
250. Miyake A (1995) A truncated isoform of human CCK-B/gastrin receptor generated by alternative usage of a novel exon. Biochem Biophys Res Commun 208:230-237.
251. Montgomery SA and Green MC (1988) The use of cholecystokinin in schizophrenia: a review. Psychol Med 18:593-603.
252. Moons L, Batten TF and Vandesande F (1992) Comparative distribution of substance P (SP) and cholecystokinin (CCK) binding sites and immunoreactivity in the brain of the sea bass (Dicentrarchus labrax). Peptides 13:37-46.
253. Moran TH, Ameglio PJ, Peyton HJ, Schwartz GJ and McHugh PR (1993) Blockade of type A, but not type B, CCK receptors postpones satiety in rhesus monkeys. Am J Physiol 265:R620-R624.
254. Moran TH, Ameglio PJ, Schwartz GJ and McHugh PR (1992) Blockade of type A, not type B, CCK receptors attenuates satiety actions of exogenous and endogenous CCK. Am J Physiol 262:R46-R50.
255. Moran TH and McHugh PR (1988) Anatomical and pharmacological differentiation of pyloric, vagal and brainstem cholecystokinin receptors, in Cholecystokinin Antagonists (Wang RY and Schoenfeld R eds) pp 117-132, Alan R. Liss, New York.
256. Moran TH, Norgren R, Crosby RJ and McHugh PR (1990) Central and peripheral transport of vagal cholecystokinin binding sites occurs in afferent fibers. Brain Res 362:175-179.
257. Moran TH, Robinson PH, Goldrich MS and McHugh PR (1986) Two brain cholecystokinin receptors: Implications for behavioral actions. Brain Res 362:175-179.
258. Moran TH, Smith GP, Hostetler AM and McHugh PR (1987) Transport of cholecystokinin (CCK) binding sites in subdiaphragmatic vagal branches. Brain Res 415: 149-152.
259. Morency MA, Quirion R and Mishra RK (1994) Distribution of cholecystokinin receptors in the bovine brain: A quantitative autoradiographic study. Neuroscience 62:307-316.
260. Mueller K and Whiteside DA (1990) Enkephalin prevents CCK-induced enhancement of amphetamine-induced locomotor stereotypy. Brain Res 513:119-124.
261. Müller S and Lohse MJ (1995) The role of G-protein beta gamma subunits in signal transduction. Biochem Soc Trans 23:141-148.
262. Munro G, Pumford KM and Russell JA (1998) Altered cholecystokinin binding density in the supraoptic nucleus of morphine-tolerant and -dependent rats. Brain Res 780:190-198.
263. Nadzan AM, Garvey DS, Holladay MW, Shiosaki K, Tufano MD, Shue YK, Chung JYL, May PD, May GS, Lin CW, Miller TR, Witte DG, Bianchi BR, Wolfram CAW, Burt S and Hutchins GW (1991) Design of cholecystokinin analogs with high affinity and selectivity for brain receptors, in Peptides: Chemistry and Biology. Proceedings of the 12th American Peptide Symposium June 16-21, 1991, Cambridge, MA (Smith JA and Rivier JE eds) pp 101-102, ESCOM, Leiden.
264. Nagata A, Ito M, Iwata N, Kuno J, Takano H, Minowa O, Chihara K, Matsui T and Noda T (1996) G protein-coupled cholecystokinin-B/gastrin receptors are responsible for physiological cell growth of the stomach mucosa in vivo. Proc Natl Acad Sci USA 93:11825-11830.
265. Nakata H, Matsui T, Ito M, Taniguchi T, Naribayashi Y, Arima N, Nakamura A, Kinoshita Y, Chihara K, Hosoda S and Chiba T (1992) Cloning and characterization of gastrin receptor from ECL carcinoid tumor of Mastomys natalensis. Biochem Biophys Res Commun 187:1151-1157.
266. 125I-Bolton-Hunter CCK8. Peptides 10:265-274.
267. Nishida A, Miyata K, Tsutsumi R, Yuki H, Akuzawa S, Kobayashi A, Kamato T, Ito H, Yamano M, Katuyama Y, Satoh M, Ohta M and Honda K (1994) Pharmacological profile of (R)-1-[2,3-dihydro-1-(2′-methyl-phenacyl)-2-oxo-5-phenyl-1H-1,4- benzodiazepin-3-yl]-3-(3-methylphenyl)urea (YM022), a new potent and selective gastrin/cholecystokinin-B receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 269:725-731.
268. Noble F, Derrien M and Roques BP (1993) Modulation of opioid analgesia by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain. Br J Pharmacol 109:1064-1070.
269. O'Dowd B, Hnatowich M, Caron MG, Lefkowitz RJ and Bouvier M (1988) Site-directed mutagenesis of the cytoplasmatic domains of the human β-2 adrenergic receptor: Localization of regions involved in G-protein-receptor coupling. J Biol Chem 264:7564-7569.
270. O'Neill MF, Dourish CT and Iversen SD (1991) Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCK-A receptor antagonist devazepide but not by the CCK-B receptor antagonist L-365,260. Eur J Pharmacol 193:203-208.
271. O'Shea RD and Gundlach AL (1995) Activity-linked alterations in cholecystokininB receptor messenger RNA levels in magnocellular hypothalamic neurones by food and water deprivation in the rat. Neurosci Lett 194:189-192.
272. Oliver AS and Vigna SR (1996) CCK-X receptors in the endothermic mako shark (Isurus oxyrinchus). Gen Comp Endocrinol 102:61-73.
273. Ondetti MA, Rubin B, Engel SL, Pluscec J and Sheehan JT (1970) Cholecystokinin-pancreozymin. Recent developments Am J Dig Dis 15:149-156.
274. Ovchinikov YA, Ablulajew NG and Bogachuck AS (1988) Two adjacent cysteine residues in the C-terminal cytoplasmatic fragment of bovine rhodopsin are palmitoylated. FEBS Lett 230:1-5.
275. Ozcelebi F and Miller LJ (1995) Phosphopeptide mapping of cholecystokinin receptors on agonist-stimulated native pancreatic acinar cells. J Biol Chem 270:3435-3441.
276. Padia JK, Chilvers H, Daum P, Pinnock R, Suman-Chauhan N, Webdale L and Trivedi BK (1997) Design and synthesis of novel nonpeptide CCK-B receptor antagonists. Bioorg Med Chem Lett 7:805-810.
277. Padia JK, Field M, Hinton J, Meecham K, Pablo J, Pinnock R, Roth BD, Singh L, Suman-Chauhan N, Trivedi BK and Webdale L (1998) Novel nonpeptide CCK-B antagonists: Design and development of quinazolinone derivatives as potent, selective, and orally active CCK-B antagonists. J Med Chem 41:1042-1049.
278. Palmour RM, Durieux C, Roques BP, Bertrand P, Capet M, Dubroeucq MC, Howbert JJ, Woodruff G, Bradwejn J and Ervin FR (1993) Anxiogenic effects of CCK agonists in a non-human primate model: Central or peripheral. CCK 1993: International Symposium; 1993 May 19-22; Chatham, Massachusetts.
279. Pandol SJ, Hsu Y, Kondratenko NF, Schoeffield-Payne MS and Steinbach JH (1991) Dual pathways for agonist-stimulated arachidonic acid release in pancreatic acini: Roles in secretion. Am J Physiol 260:G423-G433.
280. Pandol SJ, Schoeffield MS, Sachs G and Muallem S (1985) Role of free cytosolic calcium in secretagogue-stimulated amylase release from dispersed acini from guinea pig pancreas. J Biol Chem 260:10081-10086.
281. Pang IK and Sternweiss PC (1990) Purification of unique a subunits of GTP-binding regulatory proteins (G proteins) by affinity chromatography with immobilized βγ subunits. J Biol Chem 265:18707-18712.
282. Patel S, Smith AJ, Chapman KL, Fletcher AE, Kemp JA, Marshall GR, Hargreaves RJ, Ryecroft W, Iversen LL, Iversen SD, Baker R, Showell GA, Bourrain S, Neduvelil JG, Matassa VG and Freedman SB (1994) Biological properties of the benzodiazepine amide derivative L-740,093, a cholecystokinin-β/gastrin receptor antagonist with high affinity in vitro and high potency in vivo. Mol Pharmacol 46:943-948.
283. Payeur R, Nixon MK, Bourin M, Bradwejn J and Legrand JM (1993) The potential role of cholecystokinin in schizophrenia: Review and update. Eur Psychiatry 8:67-78.
284. Pearson RK and Miller LJ (1987) Affinity labeling of a novel cholecystokinin-binding protein in rat pancreatic plasmalemma using new short probes for the receptor. J Biol Chem 262:869-876.
285. Pearson RK, Miller LJ, Hadac EM and Powers SP (1987a) Analysis of the carbohydrate composition of the pancreatic plasmalemmal glycoprotein affinity labeled by short probes for the cholecystokinin receptor. J Biol Chem 262:13850-13856.
286. Pearson RK, Miller LJ, Powers SP and Hadac EM (1987b) Biochemical characterization of the pancreatic cholecystokinin receptor using monofunctional photoactivatable probes. Pancreas 2:79-84.
287. Pendley CE, Fitzpatrick LR, Capolino AJ, Davis MA, Esterline NJ, Jakubowska A, Bertrand P, Guyon C, Dubroeucq MC and Martin GE (1995) RP 73870, a gastrin/ cholecystokinin-B receptor antagonist with potent anti-ulcer activity in the rat. J Pharmacol Exp Ther 273:1015-1022.
288. 8. Neurochem Int 10: 495-508.
289. Pi-Sunyer X, Kissileff HR, Thornton J and Smith GP (1982) C-terminal octapeptide of cholecystokinin decreases food intake in obese men. Physiol Behav 29:627-630.
290. Pierson ME, Comstock JM, Simmons RD, Kaiser F, Julien R, Zongrone J and Rosamond JD (1997) Synthesis and biological evaluation of potent, selective, hexapeptide CCK-A agonist anorectic agents. J Med Chem 40:4302-4307.
291. Piiper A, Stryjek-Kaminska D, Klengel R and Zeuzem S (1997) CCK, carbachol, and bombesin activate distinct PLC-beta isoenzymes via Gq/11 in rat pancreatic acinar membranes. Am J Physiol 272:G135-G140.
292. Pisegna JR, de Weerth A and Wank SA (1992) Molecular cloning of the human brain and gastric cholecystokinin receptor: Structure, functional expression and chromosomal localization. Biochem Biophys Res Commun 189:296-303.
293. Ploeger GE, Spruijt BM and Cools AR (1994) Spatial localization in the Morris water maze in rate: Acquisition is affected by intra-accumbens injections of the dopaminergic antagonist haloperidol. Behav Neurosci 108:927-934.
294. 5-enkephalin-, and dynorphin A (1-8)-like materials in the spinal cord and dorsal root ganglia of adult rats: Effects of dorsal rhizotomy and neonatal capsaicin. J Neurochem 55:1122-1130.
295. Pohl M, Silvente-Poirot S, Pisegna JR, Tarasova NI and Wank SA (1997) Ligand-induced internalization of cholecystokinin receptors. J Biol Chem 272:18179-18184.
296. Pommier B, Da Nascimento S, Dumont S, Bellier B, Million E, Garbay C, Roques BP and Noble F (1999) The CCK-B receptor is coupled to two effector pathways through pertussis toxin sensitive and insensitive G proteins. JNeurochem 73:281-288.
297. Powers SP, Foo I, Pinon D, Klueppelberg UG, Hedstrom JF and Miller LJ (1991) Use of photoafffinity probes containing polyethyleneglycol spacers for topographical mapping of the cholecystokinin receptor complex. Biochemistry 30:676-682.
298. 125I-CCK-8 probe resistant to degradation. J Neurochem 40:1406-1413.
299. Qian M, Johnson AE, Kallstrom L, Carrer H and Sodersten P (1997) Cholecystokinin, dopamine D2 and N-methyl-D-aspartate binding sites in the nucleus of the solitary tract of the rat: Possible relationship to ingestive behavior. Neuroscience 77:1077-1089.
300. Rao RV, Roettger BF, Hadac EM and Miller LJ (1997) Roles of cholecystokinin receptor phosphorylation in agonist-stimulated desensitization of pancreatic acinar cells and receptor-bearing Chinese hamster ovary cholecystokinin receptor cells. Mol Pharmacol 51:185-192.
301. Rattray M and De Belleroche J (1987) Morphine action on cholecystokinin octapeptide release from rat periaqueductal grey slices: Sensitization by naloxone. Neuropeptides 10:189-200.
302. Rehfeld JH and Nielsen FC (1995) Molecular forms and regional distribution of cholecystokinin in the central nervous system, in Cholecystokinin and Anxiety (Bradwejn J and Vasar E eds) pp 33-56, RG Landes Company, Austin.
303. Reidelberger RD, Varga G and Solomon TE (1991) Effects of selective cholecystokinin antagonists L364,718 and L365,260 on food intake in rats. Peptides 12:1215-1221.
304. Reuben M, Rising L, Prinz C, Hersey S and Sachs G (1994) Cloning and expression of the rabbit gastric CCK-A receptor. Biochim Biophys Acta 1219:321-327.
305. Reubi JC, Schaer JC and Waser B (1997a) Cholecystokinin (CCK)-A and CCK-B/ gastrin receptors in human tumors. Cancer Res 57:1377-1386.
306. Reubi JC and Waser B (1996) Unexpected high incidence of cholecystokinin-B/ gastrin receptors in human medullary thyroid carcinomas, Int J Cancer 67:644-647.
307. Reubi JC, Waser B, Laderach U, Stettler C, Friess H, Halter F and Schmassmann A (1997b) Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach. Gastroenterology 112:1197-1205.
308. Roche S, Bali JP and Magous R (1990) Involvement of a pertussis toxin-sensitive G protein in the action of gastrin on gastric parietal cells. Biochim Biophys Acta 1055:287-294.
309. Rodriguez M, Lignon MF, Galas MC, Amblard M and Martinez J (1990) Cyclic cholecystokinin analogs that are highly selective for rat and guinea pig central cholecystokinin receptors. Mol Pharmacol 38:333-341.
310. Rodriguez RE and Sacristan MP (1989) In vivo release of CCK-8 from the dorsal horn of the rat: Inhibition by DAGOL. FEBS Lett 250:215-217.
311. Roques BP and Noble F (1996) Association of enkephalin catabolism inhibitors and CCK-B antagonists: A potential use in the management of pain and opioid addiction. Neurochem Res 21:1395-1409.
312. Roques BP, Noble F, Daugé V, Fournié-Zaluski MC and Beaumont A (1993) Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev 45:87-146.
313. Rose C, Vargas F, Facchinetti P, Bourgeat P, Bambal RB, Bishop PB, Chan SMT, Moore ANJ, Ganellin CR and Schwartz JC (1996) Characterization and inhibition of a cholecystokinin-inactivating serine peptidase. Nature (Lond) 380:403-409.
314. Rosenzweig SA, Miller LJ and Jamieson JD (1983) Identification and localization of cholecystokinin-binding sites on rat pancreatic plasma membranes and acinar cells: A biochemical and autoradiographic study. J Cell Biol 96:1288-1297.
315. Ruiz-GayoM, Daugé V, Menant I, Bégué D, Gacel G and Roques BP (1985) Synthesis and biological activity of Boc(Nle28,Nle31)CCK27-33 a highly potent CCK8 analog. Peptides 6:415-420.
316. Ruiz-Gayo M, Delay-Goyet P, Durieux C, Corringer PJ, Baamonde A, Gacel G and Roques BP (1990) Investigation of opioid and cholecystokinin central receptors after peripheral injection of selective and enzyme-resistant peptides. J Control Release 13:147-155.
317. 3H]pBC264: Evidence for a physiological regulation of CCKergic systems by endogenous enkephalins. J Neurochem 59:1805-1811.
318. Sacerdote P, Wiedermann CJ, Wahl LM, Pert CB and Ruff MR (1991) Visualization of cholecystokinin receptors on a subset of human monocytes and in rat spleen. Peptides 12:167-176.
319. Saito AH, Sankaran H, Goldfine ID and Williams JA (1980) Cholecystokinin receptors in the brain: Characterization and distribution. Science (Wash DC) 208:1155-1156.
320. Sandvik AK and Waldum HL (1991) CCK-B (gastrin) receptor regulates gastric histamine release and acid secretion. Am J Physiol 260:G925-G928.
321. Sankaran H, Deveney CW, Godfine ID and Williams JA (1979) Preparation of biologically active radioiodinated cholecystokinin for radioreceptor assay and radioimmunoassay. J Biol Chem 254:9349-9351.
322. Sankaran H, Goldfine ID, Deveney CW, Wong KY and Williams JA (1980) Binding of cholecystokinin to high affinity receptors on isolated rat pancreatic acini. J Biol Chem 255:11849-11853.
323. Satoh Y, Matsuo T, Sogabe H, Itoh H, Tada T, Kinoshita T, Yoshida K and Takaya T (1994) Studies on a novel, potent and orally effective cholecystokinin A antagonist, FK480: Synthesis and structure-activity relationships of FK480 and related compounds. Chem Pharm Bull (Tokyo) 42:2071-2083.
324. Schalling M, Friberg K, Seroogy K, Riederer P, Bird E, Schiffmann SN, Mailleux P, Vanderhaeghen JJ, Kuga S and Goldstein M (1990) Analysis of expression of cholecystokinin in dopamine cells in the ventral mesencephalon of several species and in humans with schizophrenia. Proc Natl Acad Sci USA 87:8427-8431.
325. Schiffmann SN, Goldman S, Heyman P, De Vuyst M, De Roy G and Vanderhaeghen JJ (1992) Ontogeny of cholecystokinin receptors in the human striatum, Neurosci Lett 141:39-42.
326. Schjoldager B, Shaw MJ, Powers SA, Schmalz PH, Szurszewski J and Miller LJ (1988) Bovine gallbladder muscularis: Source of a myogenic receptor for cholecystokinin. Am J Physiol 254:G294-G299.
327. Schmitz F, Pratt DS, Wu M-J, Kolakowski LF, Beinborn M and Kopin AS (1996) Identification of cholecystokinin-B/gastrin receptor domains that confer high gastrin affinity: Utilization of a novel Xenopus laevis cholecystokinin receptor. Mol Pharmacol 50:436-441.
328. Schreiber H, Stolz-Born G, Pietrowsky R, Kornhuber HH, Fehm HL and Born J (1995) Improved event-related potential signs of selective attention after the administration of the cholecystokinin analog ceruletide in healthy persons. Biol Psychiatry 37:702-712.
329. Schubert ML and Shamburek RD (1990) Control of acid secretion. Gasterenterol Clin North Am 19:1-25.
330. Sebret A, Léna I, Crété D, Matsui T, Roques BP and Daugé V (1999) Rat hippocampal neurons are critically involved in physiological improvement of memory processes induced by cholecystokinin-B receptor stimulation. J Neurosci 19:7230-7237.
331. Sekiguchi R and Moroji T (1986) A comparative study on characterization and distribution of cholecystokinin binding sites among the rat, mouse and guinea pig brain. Brain Res 399:271-281.
332. Semple G, Ryder H, Kendrick DA, Szelke M, Ohta M, Satoh M, Nishida A, Akuzawa S and Miyata K (1996a) Synthesis and biological activity of 1-alkylcarbonyl methyl analogs of YM 022. Bioorg Med Chem Lett 6:51-54.
333. Semple G, Ryder H, Kendrick DA, Szelke M, Ohta M, Satoh M, Nishida A, Akuzawa S and Miyata K (1996b) Synthesis and biological activity of 5-heteroaryl benzodiazepines: Analogues of YM 022. Bioorg Med Chem Lett 6:55-59.
334. Semple G, Ryder H, Rooker DP, Batt AR, Kendrick DA, Szelke M, Ohta M, Satoh M, Nishida A, Akuzawa S and Miyata K (1997) (3A)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4- benzodiazepin-3-y1)-N′-(3-(methylamino) phenyl)urea (YF476): A potent and orally active gastrin/CCK-B antagonist. J Med Chem 40:331-341.
335. 2+ mobilization and clonal growth. Cancer Res 53:5208-5213.
336. Shaw MJ, Madac EM and Miller LJ (1987) Preparation of enriched plasma membranes from bovine gallbladder muscularis for characterization of cholecystokinin receptors. J Biol Chem 262:14313-14318.
337. Sherrington R, Mankoo B, Attwood J, Kalsi G, Curtis D, Buetow K, Povey S and Gurling H (1993) Cloning of the human dopamine D5 receptor gene and identification of a highly polymorphic microsatellite for the DRD5 locus that shows tight linkage to the chromosome 4p reference marker RAF1P1. Genomks 18:423-425.
338. Shigeyoshi Y, Okamura H, Inatomi T, Matsui T, Ito M, Kaji H, Abe H, Nakata H, Chiba T and Chihara K (1994) Distribution of mRNA for CCK-B receptor in the brain of Mastomys natalensis: Abundant expression in telencephalic neurons. Brain Res 640:81-92.
339. 4, in Peptides: Chemistry, Structure and Biology. Proceedings of the 11th American Peptide Symposium, July 9-14, 1989, La Jolla, CA (Rivier JE and Marshall GR eds) pp 978-980, ESCOM, Leiden.
340. Shlik J, Aluoja A, Vasar V, Vasar E, Podar T and Bradwejn J (1997a) Effects of citalopram treatment on behavioural, cardiovascular, and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci 22:332-340.
341. Shlik J, Koszycki D and Bradwejn J (1998) Decrease in short-term memory function induced by CCK-4 in healthy volunteers. Peptides 19:969-975.
342. Shlik J, Vasar E and Bradwejn J (1997b) Cholecystokinin and psychiatric disorders: Role in aetiology and potential of receptor antagonists in therapy. CNS Drugs 8:134-152.
343. Showell GA, Bourrain S, Neduvelil JG, Fletcher SR, Baker R, Watt AP, Fletcher AE, Freedman SB, Kemp JA, Marshall GR, Patel S, Smith GR and Matassa VG (1994) High-affinity and potent, water-soluble 5-amino-1,4-benzodiazepine CCK-B/ gastrin receptor antagonists containing a cationic solubilizing group. J Med Chem 37:719-721.
344. Silvente-Poirot S, Dufresne M, Vaysse N and Fourmy D (1993a) The peripheral cholecystokinin receptors. Eur J Biochem 215:513-529.
345. Silvente-Poirot S, Hadjiivanova C, Escrieut C, Dufresne M, Martinez J, Vaysse N and Fourmy D (1993b) Study of the states and populations of the rat pancreatic cholecystokinin receptor using the full peptide antagonist JMV 179. Eur J Biochem 212:529-538.
346. Silvente-Poirot S and Wank SA (1996) A segment of five amino acids in the second extracellular loop of the cholecystokinin-B receptor is essential for selectivity of the peptide agonist gastrin. J Biol Chem 271:14698-14706.
347. Silvente-Poirot SS, Escrieut C and Wank SA (1998) Role of the extracellular domains of the cholecystokinin receptor in agonist binding. Mol Pharmacol 54:364-371.
348. Simmons RD, Blosser JC and Rosamond JR (1994) FPL 14294: A novel CCK-8 agonist with potent intranasal anorectic activity in the rat. Pharmacol Biochem Behav 47:701-708.
349. Smadja C, Maldonado R, Turcaud S, Fournié-Zaluski MC and Roques BP (1995) Opposite role of CCK-A and CCK-B receptors in the modulation of endogenous enkephalin antidepressant-like effects. Psychopharmacology 120:400-408.
350. Smadja C, Ruiz F, Coric P, Fournié-Zaluski MC, Roques BP and Maldonado R (1997) CCK-B receptors in the limbic system modulate the antidepressant-like effects induced by endogenous enkephalins. Psychopharmacology 132:227-236.
351. Smith GP and Gibbs J (1992) The development and proof of the CCK hypothesis of satiety, in Multiple Cholecystokinin Receptors in the CNS (Dourish CT, Cooper SJ, Iversen SD and Iversen LL eds) pp 166-182, Oxford University Press, Oxford.
352. Smith GP, Jerome C, Cushin BJ, Eterno R and Simansky KJ (1981) Abdominal vagotomy blocks the satiety effect of cholecystokinin in the rat. Science (Wash DC) 213:1036-1037.
353. Smith GP, Moran TH, Coyle JT, Kuhar MJ, O'Donahue TL and McHugh PR (1984) Anatomical localization of cholecystokinin receptors to the pyloric sphincter. Am J Physiol 246:R127-R130.
354. Song I, Brown DR, Wiltshire RN, Gantz I, Trent JM and Yamada T (1993) The human gastrin/cholecystokinin type B receptor gene: Alternative splice donor site in exon 4 generates two variant mRNAs. Proc Natl Acad Sci USA 90:9085-9089.
355. Song M, Wong H, Ohning G and Walsh JH (1996) Immunohistochemical localization of the gastrin/CCK-B receptor in the rat stomach. Gastroenterology 110:A1120.
356. South EH and Ritter RC (1988) Capsaicin application to central or peripheral vagal fibers attenuates CCK satiety. Peptides 9:601-612.
357. Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, Seeburg PH and Journot L (1993) Differential signal transduction by five splice variants of the PACAP receptor. Nature (Lond) 365:170-174.
358. Stacher G, Steinringer H, Schmierer G, Schneider C and Winklehner S (1982) Cholecystokinin octapeptide decreases intake of solid food in man. Peptides 3:133-136.
359. 3H]PD 140376. Regul Pept 65:37-43.
360. 125I]-cholecystokinin to pancreatic plasma membranes: Evidence for a disulfide-linked Mr 76000 peptide in cholecystokinin receptors. Peptides 4:163-172.
361. Szecowka J, Hallden G, Goldfine ID and Williams JA (1989) Purification of the pancreatic cholecystokinin receptor. Regul Pept 24:215-224.
362. Taghzouti K, Léna I, Dellu F, Roques BP, Daugé V and Simon H (1999) Cognitive enhancing effects in young and old rats of pBC 264, a selective CCK-B receptor agonist. Psychopharmacology 143:141-149.
363. Taghzouti K, Louilot A, Herman JP, LeMoal M and Simon H (1985) Alternation behaviour, spatial discrimination and reversal disturbances following 6-OHDA lesions in the nucleus accumbens of the rat. Behav Neural Biol 44:354-363.
364. Takata Y, Takiguchi S, Funakoshi A, Kono S and Aono A (1995) Gene structure of rat cholecystokinin type-A receptor. Biochem Biophys Res Commun 213:958-966.
365. Takiguchi S, Takata Y, Funakoshi A, Miyasaka K, Kataoka K, Fujimura Y, Goto T and Kono A (1997) A disrupted cholecystokinin type-A receptor (CCKAR) gene in OLETF rats. Gene 197:169-175.
366. Talkad VD, Fortune KP, Pollo DA, Shah GN, Wank SA and Gardner JD (1994) Direct demonstration of three different states of the pancreatic cholecystokinin receptor. Proc Natl Acad Sci USA 91:1868-1872.
367. Taniguchi H, Yazaki N, Yomota E, Shikano T, Endo T and Nagasaki M (1996) Pharmacological profile of T-0632, a novel potent and selective CCK-A receptor antagonist, in vivo. Eur J Pharmacol 312:227-233.
368. MAP. Oncogene 9:861-867.
369. Tarasova NI, Romanov VI, Da Silva PP and Michejda CJ (1996) Numerous cell targets for gastrin in the guinea pig stomach revealed by gastrin/CCKB receptor localization. Cell Tissue Res 283:1-6.
370. Tarasova NI, Stauber RH, Choi JK, Hudson EA, Czerwinski G, Miller JL, Pavlakis GN, Michejda CJ and Wank SA (1997) Visualization of G protein-coupled receptor trafficking with the aid of the green fluorescent protein. J Biol Chem 272:14817-14824.
371. Tateishi K, Funakoshi A, Misumi Y and Matsuoka Y (1998) Jun and MAP kinases are activated by cholecystokinin in the pancreatic carcinoma cell line KP-1N. Pancreas 16:499-504.
372. Trivedi BK, Padia JK, Holmes A, Rose S, Wright DS, Hinton JP, Prithchard MC, Eden JM, Kneen C, Webdale L, Suman-Chauhan N, Boden P, Singh L, Field MJ and Hill D (1998) Second generation "peptoid" CCK-B receptor antagonists: Identification and development of N-(adamantyloxycarbonyl)-α-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile. J Med Chem 41:38-45.
373. Tsunoda Y, Song I, Taylor LP and Owyang C (1997) Molecular interaction between CCK ligands and the CCKA receptor. Gastroenterology 112:A-3403.
374. Tsunoda Y, Takeda H, Asaka M, Nakagaki I and Sasaki S (1988a) Initial and sustained calcium mobilizations in the parietal cell during stimulations with gastrin, inositol triphosphate, phorbol ester and exogenous diacylglycerol. FEBS Lett 232:83-90.
375. 2+ ionophore treatment: Comparison between luminescent and fluorescent probes and electron probe X-ray microanalyzer. Biochem Cell Biol 66:279-287.
376. Tsunoda Y, Yodozawa S and Tashiro Y (1989) Heterogeneous distribution of free calcium and propagation of calcium transient in gastric parietal cells revealed by digital imaging microscopy. J Histochem Cytochem 37:999-1005.
377. Ulrich CD, Ferber I, Holicky E, Hadac E, Buell G and Miller LJ (1993) Molecular cloning and functional expression of the human gallbladder cholecystokinin A receptor. Biochem Biophys Res Commun 193:204-211.
378. Valverde O, Maldonado R, Fournié-Zaluski MC and Roques BP (1994) Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. J Pharmacol Exp Ther 270:77-88.
379. Van Bree L, Zhang F, Schiffmann SN, Halleux P, Mailleux P and Vanderhaeghen JJ (1995) Homolateral cerebrocortical changes in neuropeptide and receptor expression after minimal cortical infarction. Neuroscience 69:847-858.
380. 3H]cholecystokinin-8 as radioligand. J Neurosci 4:1021-1031.
381. van Megen HG, Westenberg HG, den Boer JA, Haigh JR and Traub M (1994) Pentagastrin induced panic attacks: Enhanced sensitivity in panic disorder patients. Psychopharmacology 114:449-455.
382. van Megen HG, Westenberg MG, den Boer JA, Slaap B and Scheepmakers A (1997) Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4-induced panic attacks. Psychopharmacology 129:357-364.
383. van Vliet IM, Westenberg HG, Slaap BR, den Boer JA and Ho Pian KL (1997) Anxiogenic effects of pentagastrin in patients with social phobia and healthy controls. Biol Psychiatry 42:76-78.
384. Vanderhaeghen JJ, Signeau JC and Gepts W (1975) New peptide in vertebrate CNS reacting with antigastrin antibodies. Nature (Lond) 257:601-605.
385. Vanhoutte PM, Humphrey PPA and Spedding M (1996) XI. International Union of Pharmacology. Recommendations for nomenclature of new receptor subtypes. Pharmacol Rev 48:1-2.
386. Vigna S, Steigerwalt RW and Williams JA (1984) Characterization of cholecystokinin receptors in bullfrog (Rana catesbeiana) brain and pancreas. Regul Pept 9:199-212.
387. Vigna SR, Thorndyke MC and Williams JA (1986) Evidence for a common evolutionary origin of brain and pancreas cholecystokinin receptors. Proc Natl Acad Sci USA 83:4355-4359.
388. Virgo L, Humphries C, Mortimer A, Barnes T, Hirsch S and de Belleroche J (1995) Cholecystokinin messenger RNA deficit in frontal and temporal cerebral cortex in schizophrenia. Biol Psychiatry 37:694-701.
389. Wang H-L (1997) Basic amino acids at the C-terminus of the third intracellular loop are required for the activation of phospholipase C by cholecystokinin-B receptors. J Neurochem 68:1728-1735.
390. Wang Z, Valdes J, Noyes R, Zoega T and Crowe RR (1998) Possible association of a cholecystokinin promoter polymorphism (CCK-36CT) with panic disorder. Am J Med Genet 81:228-234.
391. Wank SA (1995) Cholecystokinin receptors. Am J Physiol 269:G628-G646.
392. Wank SA, Harkins RT, Jensen RT, Shapira H, de Weerth A and Slattery T (1992a) Purification, molecular cloning, and functional expression of the cholecystokinin receptor from rat pancreas. Proc Natl Acad Sci USA 89:3125-3129.
393. Wank SA, Pisegna JR and de Weerth A (1992b) Brain and gastrointestinal cholecystokinin receptor family: Structure and functional expression. Proc Natl Acad Sci USA 89:8691-8695.
394. Wank SA, Pisegna JR and de Weerth A (1994a) Cholecystokinin receptor family: Molecular cloning, structure, and functional expression in rat, guinea pig, and human. Ann NY Acad Sci 713:49-66.
395. Wank SA, Pisegna JR and Poirot SS (1994b) Functional significance of potential splice variants of the human cholecystokinin (CCK) B receptor. Gastroenterology 106:A570.
396. Weinberg DS, Ruggeri B, Barber MT, Biswas S, Miknyocki S and Waldman SA (1997) Cholecystokinin A and B receptors are differentially expressed in normal pancreas and pancreatic adenocarcinoma. J Clin Invest 100:597-603.
397. 4 bioactive conformation. Regul Pept 65:3-9.
398. 2 derivatives. Bioorg Med Chem. 4:563-573.
399. Wennogle L, Wysowskyj H, Steel DJ and Petrack B (1988) Regulation of central cholecystokinin recognition sites by guanyl nucleotides. J Neurochem 50:954-963.
400. Wettstein JG, Bueno L and Junien JL (1994) CCK antagonists: Pharmacology and therapeutic interest. Pharmacol Ther 62:267-282.
401. Whiteford HA, Stedman TJ, Welham J, Csernansky JG and Pond SM (1992) Placebo-controlled, double-blind study of the effects of proglumide in the treatment of schizophrenia. J Clin Psychopharmacol 12:337-340.
402. Widdop RE, Krstew E, Mercer LD, Carlberg M, Beart PM and Jarrott B (1994) Electrophysiological and autoradiographical evidence for cholecystokinin A receptors on rat isolated nodose ganglia. J Auton Nerv Syst 46:65-73.
403. Williams JA, Gryson KA and McChesney DJ (1986) Brain CCK receptors: species differences in regional distribution and selectivity. Peptides 7:293-296.
404. Willner P (1990) Animal models of depression: An overview. Pharmacol Ther 45: 425-455.
405. Willson TM, Henke BR, Momtahen TM, Myers PL, Sugg EE, Unwalla RJ, Croom DK, Dougherty RW, Grizzle MK, Johnson MF, Queen KL, Rimele TJ, Yingling JD and James MK (1996) 3-[2-(N-phenylacetamide)]-1,5-Benzodiazepines: Orally active, binding selective CCK-A agonists. J Med Chem 39:3030-3034.
406. Wolkowitz OM, Gertz B, Weingartner H, Beccaria L, Thompson K and Liddle RA (1990) Hunger in humans induced by MK-329, a specific peripheral-type cholecystokinin receptor antagonist. Biol Psychiatry 28:169-173.
407. Woodruff GN, Hill DR, Boden P, Pinnock R, Singh L and Hughes J (1991) Functional role of brain CCK receptors. Neuropeptides 19 (Suppl):45-56.
408. Wu V, Yang M, McRoberts JA, Ren J, Seensalu R, Zeng N, Dagrag M, Birnbaumer M and Walsh JH (1997) First intracellular loop of the human cholecystokinin-A receptor is essential for cyclic AMP signaling in transfected HEK-293 cells. J Biol Chem 272:9037-9042.
409. Yoshida H, Tsunoda Y and Owyang C (1997) Cholecystokinin peptides stimulate pancreatic secretion by multiple signal transduction pathways. Am J Physiol 273:G735-G747.
410. Yu MJ, Trasher KJ, McCowan JR, Mason NR and Mendelsohn LG (1991) Quinazolinone cholecystokinin-B receptor ligands. J Med Chem 34:1505-1508.
411. Yule DI, Tseng MJ, Williams JA and Logsdon CD (1993) A cloned CCK-A receptor transduces multiple signals in response to full and partial agonists. Am J Physiol 265:G999-G1004.
412. Zacharko RM, Koszycki D, Mendella PD and Bradwejn J (1995) Behavioral, neurochemical, anatomical and electrophysiological correlates of panic disorder: Multiple transmitter interaction and neuropeptide colocalization Prog Neurobiol 47: 371-423.
413. 3H]-SR 27897B: A selective probe for autoradiographic labelling of CCK-A receptors in the brain. J Recept Signal Transduct Res 16:93-113.
414. Zarbin MA, Innis RB, Wamsley JK, Snyder SH and Kuhar MJ (1983) Autoradio-graphic localization of cholecystokinin receptors in rodent brain. J Neurosci 3:877-906.
415. Zhang LJ, Lu XY and Han JS (1992) Influences of cholecystokinin octapeptide on phosphoinositide turnover in neonatal-rat brain cells. Biochem J 285:847-850.
416. Zhang X, Dagerlind A, Elde RP, Castel MN, Broberger C, Wiesenfeld-Hallin Z and Hökfelt T (1993) Marked increase in cholecystokinin B receptor messenger RNA levels in rat dorsal root ganglia after peripheral axotomy. Neuroscience 57:227-233.
417. Zimonjic DB, Popescu NC, Matsui T, Ito M and Chihara K (1994) Localization of the human cholecystokinin-B/gastrin receptor gene (CCKBR) to chromosome 11p15.5→p15.4 by fluorescence in situ hybridization. Cytogenet Cell Genet 65:184-185.